Literature DB >> 7828352

Endogenous and stimulated GH secretion, urinary GH excretion, and plasma IGF-I and IGF-II levels in prepubertal children with short stature after intrauterine growth retardation. The Dutch Working Group on Growth Hormone.

W J de Waal1, A C Hokken-Koelega, T Stijnen, S M de Muinck Keizer-Schrama, S L Drop.   

Abstract

OBJECTIVE: The pathophysiological mechanisms underlying the failure of catch up-growth in children with short stature after intrauterine growth retardation (IUGR) remain obscure. Since GH secretion disturbances might play a role in the growth retardation of these children we have investigated various aspects of the GH/IGF axis.
DESIGN: Cross-sectional study in one group of patients. PATIENTS: Forty prepubertal children (15 girls/25 boys; mean age (range) 7.5 years (3.4-10.8)) with short stature (height below the third centile) after IUGR, defined as a birth length below the third centile for gestational age, were studied. MEASUREMENTS: GH secretion was determined by a 24-hour plasma GH profile (sampling every 20 minutes) and, on a separate occasion, by a standard arginine provocation test (ATT). Plasma IGF-I and IGF-II levels were measured at the start of the GH profile. Urine was collected to measure urinary GH levels. Plasma and urinary GH were determined by double antibody RIA. IGF-I and IGF-II were determined by specific RIA after acid chromatography. The 24-hour GH profiles were analysed using Pulsar.
RESULTS: Endogenous GH secretion was similar for boys and girls. Boys had significantly lower mean GH levels compared to healthy controls. Forty per cent of the children met our criteria for a normal 24-hour GH profile (group A; n = 16) and 60% (n = 24) did not. We subdivided these 24 children into two groups: group B (n = 14) (children with either mean GH levels less than controls but with at least one spontaneous GH peak above 20 mU/l and children with normal mean GH levels but with no GH peak above 20 mU/l (subnormal 24-hour GH profile)) and group C (n = 10) (children with mean GH levels less than controls and no GH peak above 20 mU/l (low 24-hour GH profile)). The GH secretory abnormalities were due to a decrease in pulse amplitude, not in pulse frequency. Mean (SD) maximal GH response during ATT was 22.3 (12.1) mU/l. Nineteen children (47.5%) had a maximal GH value < 20 mU/l. Moderate, but significant, correlations were found between several 24-hour GH profile characteristics and the maximal GH response during ATT (r = 0.31-0.35; P < 0.05). Mean (SD) overnight urinary GH excretion was 3.8 (2.1) and 4.4 (3.5) microU/night for boys and girls, respectively. Compared to healthy schoolchildren, overnight urinary GH was lower in boys, but not in girls. Mean (SD) IGF-I and IGF-II SDS levels for chronological age were -0.88 (1.40) and -0.64 (1.48), respectively. Plasma IGF-I and IGF-II levels were significantly reduced compared to controls. Height SDSCA or height velocity SDSCA did not correlate with either spontaneous or stimulated GH secretion, urinary GH excretion or plasma IGF-I or IGF-II levels.
CONCLUSIONS: Our study indicates that 50-60% of children with short stature after intrauterine growth retardation have 24-hour GH profile abnormalities and/or subnormal responses to arginine provocation, while mean plasma IGF-I and IGF-II levels are significantly reduced, indicating GH insufficiency. Urinary GH excretion is lower in boys, but not in girls. The precise mechanism of the failure to catch up growth needs further elucidation. It seems justified to start clinical trials in order to investigate whether treatment with exogenous GH might be beneficial for these children.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7828352     DOI: 10.1111/j.1365-2265.1994.tb01828.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  16 in total

1.  Repeated betamethasone treatment of pregnant sheep programs persistent reductions in circulating IGF-I and IGF-binding proteins in progeny.

Authors:  Kathryn L Gatford; Julie A Owens; Shaofu Li; Timothy J M Moss; John P Newnham; John R G Challis; Deborah M Sloboda
Journal:  Am J Physiol Endocrinol Metab       Date:  2008-05-20       Impact factor: 4.310

2.  Small for gestation and growth hormone therapy.

Authors:  Archana Dayal Arya
Journal:  Indian J Pediatr       Date:  2006-01       Impact factor: 1.967

Review 3.  Fetal origins of adult disease: a paediatric perspective.

Authors:  Harriet L Miles; Paul L Hofman; Wayne S Cutfield
Journal:  Rev Endocr Metab Disord       Date:  2005-12       Impact factor: 6.514

Review 4.  Efficacy and safety of growth hormone treatment for children born small for gestational age.

Authors:  Il Tae Hwang
Journal:  Korean J Pediatr       Date:  2014-09-30

Review 5.  Current Insights into the Role of the Growth Hormone-Insulin-Like Growth Factor System in Short Children Born Small for Gestational Age.

Authors:  Judith S Renes; Jaap van Doorn; Anita C S Hokken-Koelega
Journal:  Horm Res Paediatr       Date:  2019-09-11       Impact factor: 2.852

Review 6.  Growth hormone treatment in children: review of safety and efficacy.

Authors:  Mark Harris; Paul L Hofman; Wayne S Cutfield
Journal:  Paediatr Drugs       Date:  2004       Impact factor: 3.022

Review 7.  Growth and body composition in very young SGA children.

Authors:  Jesús Argente; Otto Mehls; Vicente Barrios
Journal:  Pediatr Nephrol       Date:  2010-01-27       Impact factor: 3.714

Review 8.  New Horizons in Short Children Born Small for Gestational Age.

Authors:  Irène Netchine; Manouk van der Steen; Abel López-Bermejo; Ekaterina Koledova; Mohamad Maghnie
Journal:  Front Pediatr       Date:  2021-05-13       Impact factor: 3.418

9.  Comparative evaluation of short-term biomarker response to treatment for growth hormone deficiency in Chinese children with growth hormone deficiency born small for or appropriate for gestational age: a randomized phase IV open-label study.

Authors:  Wenli Lu; Shuixian Shen; Xiaoping Luo; Chunxiu Gong; Xuefan Gu; Yun Li; Minlian Du; Runming Jin; Queena Zhou; Wei Wang
Journal:  Ther Adv Endocrinol Metab       Date:  2013-04       Impact factor: 3.565

10.  IGF-I and IGF Binding Protein-3 Generation Tests and Response to Growth Hormone in Children with Silver-Russell Syndrome.

Authors:  Izabel C R Beserra; Márcia G Ribeiro; Paulo F Collett-Solberg; Mário Vaisman; Marília M Guimarães
Journal:  Int J Pediatr Endocrinol       Date:  2010-12-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.